Introduction
Without doubt, the long natural history of prostate cancer (CaP) is a boon to patients suffering from the disease. However, it poses issues for researchers in that the follow-up necessary for valid discussion of overall and cause-specific survival requires decades to complete.
1,2 Biochemical disease-free (bNED) survival is widely used currently as a surrogate, despite the widely recognized fact that this metric has mathematical limitations 3 and is not well associated with overall survival. 4, 5 Allowing for bNED survival as a valid end point, its determination still requires a median follow-up of several years. Thus, many have looked for other end points requiring less follow-up time. The search for reliable surrogates for bNED survival after RT has previously focused on PSA dynamics of decline [6] [7] [8] [9] [10] [11] and nadir values. 12, 13 Not surprisingly, lower nadir values correspond with better bNED survival; 12 this reflects not only treatment effect but also biology of the tumor and patient selection. Patients with low PSA pretreatment values generally constitute a more favorable prognostic group than those with higher values, and it would be expected that the former would have lower nadir values than the latter. With respect to time to nadir, while some studies have found that longer time to nadir predicts better responses, [13] [14] [15] we have previously reported no association between time to nadir and outcome. 16 Nevertheless, patients and physicians would benefit from an easily determined surrogate end point that may be obtained soon after definitive radiotherapy (RT). Several nomograms and calculations have been proposed, which take into account pretreatment variables and predict outcome after prostatectomy 17, 18 or RT; 18, 19 these could be made more accurate by taking into account the crucial biologic variable of the patient's response to treatment. This removes the mechanism from strictly being a prognostic model since it must be calculated a posteriori to some extent, but the increased value of prediction would be worthwhile if the time delay is short enough. Zagars and Pollack 20 previously described using the PSA 3 months after the completion of RT as a potential surrogate end point. This proved useful, but the median follow-up of their patients was only 24 months, and their study predated the ASTRO criteria for biochemical failure. 21 In the pilot study reported in this article, we analyzed the validity of PSA values 100 days after definitive RT as surrogates for bNED survival with significantly longer follow-up (over 5 years). If these data are supported by valid, rigorous correlation, the PSA drawn about 3 months after RT could become a standard metric for follow-up of patients with CaP.
Materials and methods
The records of the Naval Medical Center San Diego Radiation Oncology Division were screened for patients with T1-3 CaP treated after definitive external beam RT (defined as dose X66 Gy) between 1/1/88 and 12/31/ 2000. Patients receiving adjuvant or salvage RT after RP were excluded. Data were collected for patients who had never received hormonal therapy prior to PSA recurrence, if any. Demographic data are summarized in Table 1 . This retrospective process analysis did not require approval from the local Institutional Review Board. Performed prior to April 2003, it did not require patient consent for chart review.
Patients without a recorded PSA at diagnosis (n ¼ 5) and patients receiving less than 3 follow-up PSA values (n ¼ 5) were excluded from analysis. After these exclusions, a total of 214 eligible patient records were reviewed. bNED failure was determined according to the ASTRO criteria. 21 In some cases (n ¼ 10), patients were started on hormonal therapy for rising PSA without three consecutive rises; for them, bNED survival was considered to be the date at which hormone therapy started. Patients (n ¼ 36) without Gleason sums but with grade reported as well-, moderately, or poorly differentiated were assigned Gleason sums of 3, 6, and 9, respectively. Median follow-up was 64.3 months as calculated to the date of last PSA. Data collection was as of 31 December 2002.
Patients received routine follow-up every 3-4 months post-RT for the first 2 years, every 6 months for the next 2-3 years, and annually thereafter. Serum PSA values were drawn routinely at follow-up visits. Inspection of PSA values was performed at 100 days postoperatively. Since only two patients had values drawn exactly on that date, trends between values pre-and post-100 days were reviewed according to two discriminants: 100-day PSAsp4.0 and p2.5 ng/ml.
A distribution analysis of the data set was performed to examine the mean and median of parameters. Simple descriptive statistics were calculated where required. Disease-free survival was determined using the technique of Kaplan and Meier. Comparison between survival curves used the log-rank test. Multiple regression analysis was used to assess the bNED status as related to race, age, RT dose, initial PSA, stage, Gleason sum, and 100-day PSA (subsequently defined as PSA 100 ).
Results
Results are tabulated in Table 2 , and graphically presented in Figures 1 and 2 . Figure 1 reveals bNED survival curves for patients with PSA 100 values p4.0 and 44.0 ng/ml. Log-rank comparison of these two curves yields a highly significant value, Po0.001. In the former case, 8-y bNED survival was 62%. In the latter case, 8-y bNED survival was 20%. Analysis of bNED survival curves using a cutoff of 2.5 ng/ml yielded a nonsignificant value P ¼ 0.229 (Figure 2 ). Table 2 reveals that PSA 100 levels are not tightly associated with T-stage or Gleason sum, but appear well-correlated with presenting PSA. Fisher's exact test was used to assess this situation. The P-value for stage with PSA 100 levels p2.5 was 0.039; this is statistically significant, but due to an anomalous data bulge in Stage 2. Other P-values were insignificant: stage with PSA 100 level p4.0 ¼ 0.153, Gleason sum with PSA 100 level p2.5 ¼ 0.702, and Gleason sum with PSA 100 level p4.0 ¼ 0.132.
Inspection of
Cox proportional hazards regression was used to assess the simultaneous (ie multivariate) influence of the several independent variables on bNED survival. Race was included as Caucasian (77%) vs AfricanAmerican (14%) with 9% omitted; outcomes were little different. Significantly related to bNED survival were initial PSA (P ¼ 0.006), stage (P ¼ 0.001), and PSA 100 p4.0 ng/ml (P ¼ 0.002). Insignificantly related were age (P ¼ 0.887), RT dose (P ¼ 0.669), race (P ¼ 0.500), Gleason sum (P ¼ 0.091), and PSA 100 p2.5 ng/ml (P ¼ 0.128). If PSA 100 is removed from the analysis, initial PSA (P ¼ o0.001) and stage (P ¼ 0.003) remain significant, while age (P ¼ 0.853), RT dose (P ¼ 0.777), race (P ¼ 0.322), and Gleason sum (P ¼ 0.213) remain insignificant.
Discussion
Our group has been engaged for some time in optimizing follow-up protocols for cancer patients. Prior publications have addressed this topic for patients with colorectal cancer, 22 head and neck cancer, 23 and efficacy of digital rectal examination (DRE) after RT for CaP. 24 This study continues that effort. Published guidelines for follow-up of CaP patients 25-28 recommend 4-5 office visits with PSA levels, with DREs in the first posttreatment year, and a poll of American urologists 29 yielded practice pattern of 2-6 visits in the first year postprostatectomy. We have previously reported the lack of efficacy of DRE; 24 this report validates minimizing PSA blood draws for most patients. This pilot study should be validated with larger populations, but these data are potentially extremely useful in minimizing patient follow-up. Thus, follow-up maybe better targeted to patients who need it.
Others 30 have developed metrics using profiles based on clinical prognostic factors. While these maybe valuable as surrogate end points, they are generally difficult to use and interpret. The PSA 100 is neither. However, two questions are legitimately asked in the context of this brief report:
1. Why 100 days? We chose 100 days to reconcile different practices of seeing a patient in follow-up 1 month post-RT vs 3 months post-RT vs less frequently. Clearly, any duration of follow-up would do, but we chose 100 days, and then interpolated pre-and post-100-day PSA values. 2. Why a PSA cutoff of 4.0 ng/ml? We chose 4.0 ng/ml as an easy-to-remember cutpoint for PSA, and ran a separate analysis of 2.5 ng/ml as another easy-toremember value. While statistically feasible, we opted not to (a) linearly interpolate each PSA 100 value, then (b) run a continuous analysis of all the PSA 100 values Figure 1 Kaplan-Meier curves of biochemical disease-free survival for patients using a PSA 100 cutoff of p or 44.0 ng/ml. The difference is significant (log rank Po0.001). PSA at 100 days ≤ 2.5 % Figure 2 Kaplan-Meier curves of biochemical disease-free survival for patients using a PSA 100 cutoff of p or 42.5 ng/ml. The difference is not significant (log rank P ¼ 0.229).
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100-Day PSA PAS Johnstone et al to determine at which point between 4.0 and 25 ng/ml it lost significance-because the ease of remembering a cutpoint of 3.16 (for example) outweighed the simplicity of this pilot study.
It is clear that this test provides nothing more than a mechanism for patient selection. The PSA 100 using a cutoff of 4.0 ng/ml is tightly correlated with initial PSA, stage, and RT dose: profound factors predictive of 8-y bNED results. Race and age are not valuable; this confirms our previous reports in larger populations. 31, 32 This selection of patients likely to do well for a prolonged period thus minimizes necessity to follow-up routinely. The majority of CaP patients post-RT have minor symptoms and do not require DRE unless PSA is rising. 24 Our data reveal that a single PSA drawn 100 days after completing XRT yields valuable results. A value p4.0 ng/ml will reassure physician and patient that the patient has only about a 1/3 chance of bNED failure at 8 y! A value 44.0 ng/ml should be of much more concern, since it predicts a 4 out of 5 chance of biochemical failure at 8 y. These data emerge from a relatively small sample (n ¼ 214), albeit with robust follow-up. We await other centers' confirmation of our data.
